Asthma and lower airway diseasePrognostic value of cluster analysis of severe asthma phenotypes
Section snippets
Patients
A cohort of patients with severe asthma was built during a 1-year recruitment period after ethics committee approval in the outpatient clinic of Arnaud de Villeneuve's Hospital, Montpellier, France. This cohort aimed to identify relevant outcomes in patients with severe asthma based on thorough initial investigations. Thus patients with a secured diagnosis of severe asthma according to Innovative Medicine Initiative consensus were solicited to participate, and data were recorded once patients
Results
Patients' characteristics are presented in Table I. The cohort consisted of 112 patients with severe asthma with a mean age of 56 years, most of whom (54.4%) were women. Sixty-one percent had received an annual dose of steroids greater than 2 g the year before inclusion. The mean exacerbation rate was 2.33 per patient at inclusion, ranging from 0 to 7.
Table II presents the distribution according to the algorithm tree proposed in the SARP study reproduced in our own cohort, which allows
Discussion
In the present study we could not discriminate future risks in the different phenotypes of severe asthma in a real-life cohort of patients with severe asthma using longitudinal follow-up. Specifically, exacerbations, asthma symptoms, treatment load, and the level of airway obstruction did not follow different trends among the identified groups.
Cluster analyses of severe asthma are used to better understand the heterogeneity of the disease and the constant failure to adequately control symptoms
References (23)
- et al.
Severe asthma in adults: what are the important questions?
J Allergy Clin Immunol
(2007) - et al.
Novel severe wheezy young children phenotypes: boys atopic multiple-trigger and girls nonatopic uncontrolled wheeze
J Allergy Clin Immunol
(2012) - et al.
Immunologic therapeutic interventions in asthma: impact on natural history
Clin Chest Med
(2012) - et al.
Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial
Lancet
(2012) - et al.
Asthma endotypes: a new approach to classification of disease entities within the asthma syndrome
J Allergy Clin Immunol
(2011) - et al.
Severe asthma and adherence to peak flow monitoring: longitudinal assessment of psychological aspects
J Psychosom Res
(2010) - et al.
Measurement properties and interpretation of three shortened versions of the asthma control questionnaire
Respir Med
(2005) - et al.
History of serious asthma exacerbations should be included in guidelines of asthma severity
J Allergy Clin Immunol
(2007) - et al.
An integrative systems biology approach to understanding pulmonary diseases
Chest
(2010) - Global Initiative for Asthma. Update 2012. Available at: www.ginasthma.org. Accessed June 18,...
Identification of asthma phenotypes using cluster analysis in the Severe Asthma Research Program
Am J Respir Crit Care Med
Cited by (62)
Identification of Asthma Phenotypes in the Spanish MEGA Cohort Study Using Cluster Analysis
2023, Archivos de BronconeumologiaClinical Phenotypes of Patients Hospitalized for an Asthma Exacerbation: Prognostic Implications
2021, Journal of Allergy and Clinical Immunology: In PracticeDefinition and assessment of severe asthma
2020, Revue des Maladies Respiratoires ActualitesUpdate in severe asthma physiopathology and treatments
2019, Revue de Medecine InterneIdentification and prospective stability of electronic nose (eNose)–derived inflammatory phenotypes in patients with severe asthma
2019, Journal of Allergy and Clinical ImmunologyCitation Excerpt :The second novelty of this study is the assessment of stability of patients in those clusters during longitudinal follow-up. Previously, clustering techniques have been used to describe and monitor phenotypes of asthma based on clinical characteristics12,48-51 and for eNose technology focused on phenotyping broad cohorts of obstructive pulmonary diseases.27,52 However, the present study merged both approaches by using unbiased molecular profiling as a starting point for the follow-up of severe asthma phenotypes.
Synthesis no. 3. Asthma phenotypes: What are the practical applications for the management of severe asthma?
2019, Revue des Maladies Respiratoires Actualites
Disclosure of potential conflict of interest: A. Bourdin has board memberships with Boehringer Ingelheim and GlaxoSmithKline. F. Paganin is a board member for Novartis. P. Chanez has board memberships with GlaxoSmithKline, AstraZeneca, Chiesi, and Boston Scientific; has consultant arrangements with Novartis; has received research support from Jansen; has received payment for lectures from AstraZeneca, GlaxoSmithKline, Boston Scientific; and has received travel support from Chiesi, Novartis, and AstraZeneca. The rest of the authors declare that they have no relevant conflicts of interest.